BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 23260321)

  • 21. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy.
    Boelmans K; Holst B; Hackius M; Finsterbusch J; Gerloff C; Fiehler J; Münchau A
    Mov Disord; 2012 Mar; 27(3):421-7. PubMed ID: 22290788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.
    Quattrone A; Nicoletti G; Messina D; Fera F; Condino F; Pugliese P; Lanza P; Barone P; Morgante L; Zappia M; Aguglia U; Gallo O
    Radiology; 2008 Jan; 246(1):214-21. PubMed ID: 17991785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.
    Tsukamoto K; Matsusue E; Kanasaki Y; Kakite S; Fujii S; Kaminou T; Ogawa T
    Neuroradiology; 2012 Sep; 54(9):947-55. PubMed ID: 22274571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders.
    Seki M; Seppi K; Mueller C; Potrusil T; Goebel G; Reiter E; Nocker M; Kremser C; Wildauer M; Schocke M; Gizewski ER; Wenning GK; Poewe W; Scherfler C
    J Parkinsons Dis; 2019; 9(4):681-691. PubMed ID: 31450511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy - a comparative study.
    Gama RL; Távora DG; Bomfim RC; Silva CE; de Bruin VM; de Bruin PF
    Parkinsonism Relat Disord; 2010 May; 16(4):275-9. PubMed ID: 20185356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and reliable MRI diagnosis for progressive supranuclear palsy.
    Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S
    Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron deposition in subcortical nuclei of Parkinson's disease: A meta-analysis of quantitative iron-sensitive magnetic resonance imaging studies.
    Jin J; Su D; Zhang J; Lam JST; Zhou J; Feng T
    Chin Med J (Engl); 2024 May; ():. PubMed ID: 38809051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study.
    Agosta F; Kostić VS; Galantucci S; Mesaros S; Svetel M; Pagani E; Stefanova E; Filippi M
    Eur J Neurosci; 2010 Aug; 32(4):640-7. PubMed ID: 20597976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.
    Sjöström H; Surova Y; Nilsson M; Granberg T; Westman E; van Westen D; Svenningsson P; Hansson O
    Sci Rep; 2019 Apr; 9(1):6079. PubMed ID: 30988382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and diagnostic potential of R
    Beliveau V; Müller C; Steiger R; Gizewski ER; Poewe W; Seppi K; Scherfler C
    Parkinsonism Relat Disord; 2022 Aug; 101():43-48. PubMed ID: 35792337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes.
    Raffel DM; Koeppe RA; Little R; Wang CN; Liu S; Junck L; Heumann M; Gilman S
    J Nucl Med; 2006 Nov; 47(11):1769-77. PubMed ID: 17079809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
    Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
    Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations.
    Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
    Mov Disord; 2006 Jul; 21(7):989-96. PubMed ID: 16602104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy.
    Carlos AF; Sekiya H; Koga S; Pham NTT; Ali F; Botha H; Clark HM; Coon EA; Lowe V; Ahlskog JE; Trejo-Lopez JA; Dickson DW; Whitwell JL; Josephs KA
    Parkinsonism Relat Disord; 2022 Aug; 101():9-14. PubMed ID: 35752126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging.
    Eckert T; Sailer M; Kaufmann J; Schrader C; Peschel T; Bodammer N; Heinze HJ; Schoenfeld MA
    Neuroimage; 2004 Jan; 21(1):229-35. PubMed ID: 14741660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
    Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
    Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy.
    Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
    Brain; 2006 Apr; 129(Pt 4):1040-9. PubMed ID: 16455792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.